198 related articles for article (PubMed ID: 7657671)
21. VLDL activation of plasminogen activator inhibitor-1 (PAI-1) expression: involvement of the VLDL receptor.
Nilsson L; Gåfvels M; Musakka L; Ensler K; Strickland DK; Angelin B; Hamsten A; Eriksson P
J Lipid Res; 1999 May; 40(5):913-9. PubMed ID: 10224160
[TBL] [Abstract][Full Text] [Related]
22. Analysis of a two-domain binding site for the urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex in low-density-lipoprotein-receptor-related protein.
Andersen OM; Petersen HH; Jacobsen C; Moestrup SK; Etzerodt M; Andreasen PA; Thøgersen HC
Biochem J; 2001 Jul; 357(Pt 1):289-96. PubMed ID: 11415462
[TBL] [Abstract][Full Text] [Related]
23. Identification and characterization of the murine cell surface receptor for the urokinase-type plasminogen activator.
Solberg H; Løber D; Eriksen J; Ploug M; Rønne E; Behrendt N; Danø K; Høyer-Hansen G
Eur J Biochem; 1992 Apr; 205(2):451-8. PubMed ID: 1374026
[TBL] [Abstract][Full Text] [Related]
24. Very low density lipoprotein receptor from mammary gland and mammary epithelial cell lines binds and mediates endocytosis of M(r) 40,000 receptor associated protein.
Simonsen AC; Heegaard CW; Rasmussen LK; Ellgaard L; Kjøller L; Christensen A; Etzerodt M; Andreasen PA
FEBS Lett; 1994 Nov; 354(3):279-83. PubMed ID: 7957939
[TBL] [Abstract][Full Text] [Related]
25. Cellular degradation of free and inhibitor-bound tissue-type plasminogen activator--requirement for a co-receptor?
Camani C; Gavin O; Kruithof EK
Thromb Haemost; 2000 Feb; 83(2):290-6. PubMed ID: 10739388
[TBL] [Abstract][Full Text] [Related]
26. Differential inhibition of soluble and cell surface receptor-bound single-chain urokinase by plasminogen activator inhibitor type 2. A potential regulatory mechanism.
Schwartz BS
J Biol Chem; 1994 Mar; 269(11):8319-23. PubMed ID: 7907591
[TBL] [Abstract][Full Text] [Related]
27. Molecular dissection of ligand binding sites on the low density lipoprotein receptor-related protein.
Willnow TE; Orth K; Herz J
J Biol Chem; 1994 Jun; 269(22):15827-32. PubMed ID: 7515061
[TBL] [Abstract][Full Text] [Related]
28. Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase.plasminogen activator inhibitor type-1 complex. Evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes.
Nykjaer A; Petersen CM; Møller B; Jensen PH; Moestrup SK; Holtet TL; Etzerodt M; Thøgersen HC; Munch M; Andreasen PA
J Biol Chem; 1992 Jul; 267(21):14543-6. PubMed ID: 1378833
[TBL] [Abstract][Full Text] [Related]
29. The very low density lipoprotein receptor regulates urokinase receptor catabolism and breast cancer cell motility in vitro.
Webb DJ; Nguyen DH; Sankovic M; Gonias SL
J Biol Chem; 1999 Mar; 274(11):7412-20. PubMed ID: 10066806
[TBL] [Abstract][Full Text] [Related]
30. Endocytosis of urokinase-plasminogen activator inhibitor type 1 complexes bound to a chimeric transmembrane urokinase receptor.
Li H; Kuo A; Kochan J; Strickland D; Kariko K; Barnathan ES; Cines DB
J Biol Chem; 1994 Mar; 269(11):8153-8. PubMed ID: 7510679
[TBL] [Abstract][Full Text] [Related]
31. A cleavage-resistant urokinase plasminogen activator receptor exhibits dysregulated cell-surface clearance.
Nieves EC; Manchanda N
J Biol Chem; 2010 Apr; 285(17):12595-603. PubMed ID: 20177061
[TBL] [Abstract][Full Text] [Related]
32. Epithelial glycoprotein-330 mediates endocytosis of plasminogen activator-plasminogen activator inhibitor type-1 complexes.
Moestrup SK; Nielsen S; Andreasen P; Jørgensen KE; Nykjaer A; Røigaard H; Gliemann J; Christensen EI
J Biol Chem; 1993 Aug; 268(22):16564-70. PubMed ID: 8344937
[TBL] [Abstract][Full Text] [Related]
33. Plasminogen activator inhibitor 1 contains a cryptic high affinity receptor binding site that is exposed upon complex formation with tissue-type plasminogen activator.
Horn IR; van den Berg BM; Moestrup SK; Pannekoek H; van Zonneveld AJ
Thromb Haemost; 1998 Nov; 80(5):822-8. PubMed ID: 9843178
[TBL] [Abstract][Full Text] [Related]
34. The second and fourth cluster of class A cysteine-rich repeats of the low density lipoprotein receptor-related protein share ligand-binding properties.
Neels JG; van Den Berg BM; Lookene A; Olivecrona G; Pannekoek H; van Zonneveld AJ
J Biol Chem; 1999 Oct; 274(44):31305-11. PubMed ID: 10531329
[TBL] [Abstract][Full Text] [Related]
35. Demonstration of a specific clearance receptor for tissue-type plasminogen activator on rat Novikoff hepatoma cells.
Nguyen G; Self SJ; Camani C; Kruithof EK
J Biol Chem; 1992 Mar; 267(9):6249-56. PubMed ID: 1313432
[TBL] [Abstract][Full Text] [Related]
36. Binding of human single chain urokinase to Chinese Hamster Ovary cells and cloning of hamster u-PAR.
Fowler B; Mackman N; Parmer RJ; Miles LA
Thromb Haemost; 1998 Jul; 80(1):148-54. PubMed ID: 9684801
[TBL] [Abstract][Full Text] [Related]
37. Urokinase-type plasminogen activator receptor is internalized by different mechanisms in polarized and nonpolarized Madin-Darby canine kidney epithelial cells.
Vilhardt F; Nielsen M; Sandvig K; van Deurs B
Mol Biol Cell; 1999 Jan; 10(1):179-95. PubMed ID: 9880335
[TBL] [Abstract][Full Text] [Related]
38. Identification of determinants involved in binding of tissue-type plasminogen activator-plasminogen activator inhibitor type 1 complexes to HepG2 cells.
Morton PA; Owensby DA; Wun TC; Billadello JJ; Schwartz AL
J Biol Chem; 1990 Aug; 265(24):14093-9. PubMed ID: 2167306
[TBL] [Abstract][Full Text] [Related]
39. Regulation of the ligand binding activity of the human very low density lipoprotein receptor by protein kinase C-dependent phosphorylation.
Sakthivel R; Zhang JC; Strickland DK; Gåfvels M; McCrae KR
J Biol Chem; 2001 Jan; 276(1):555-62. PubMed ID: 11010963
[TBL] [Abstract][Full Text] [Related]
40. Two-chain urokinase, receptor, and type 1 inhibitor in cultured human mesangial cells.
Glass WF; Kreisberg JI; Troyer DA
Am J Physiol; 1993 Mar; 264(3 Pt 2):F532-9. PubMed ID: 8384415
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
